Development of morphea during Nivolumab treatment

Australas J Dermatol. 2022 May;63(2):269-271. doi: 10.1111/ajd.13834. Epub 2022 Mar 24.

Maria Fabregat-Pratdepadua¹, Aram Boada^{1

2}, José Luis Manzano³, Isabel Bielsa^{1

2}, Júlia Verdaguer-Faja¹, Ariadna Quer Pi-Sunyer^{4

5}, José-Manuel Carrascosa^{1

2}

¹ Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Institut Investigació Germans Trias i Pujol (IGTP), Spain.
² Universitat Autònoma de Barcelona, Cerdanyola del Vallés, Spain.
³ Department of Medical Oncology, ICO-Badalon, Badalona, Barcelona, Spain.
⁴ Department of Nuclear Medicine-PET, Hospital Universitari de Bellvitge, Universitat de Barcelona, Hospitalet de Llobregat, Barcelona, Spain.
⁵ Department of Pathology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.

No abstract available

Keywords: immunotherapy; melanoma; nivolumab; scleroderma.

Publication types